Celerion has been highlighted as an industry leader by highly experienced global biopharmaceutical executives in Life Science Leader’s annual CRO Leadership Awards for 2016.

Celerion was recognized across multiple categories amongst 65 of their peers including Covance, Quintiles and PPD in the annual Contract Research Quality Benchmarking online survey conducted by Industry Standard Research. The survey queried the direct client experience across 27 different performance metrics spanning technical expertise to client service; results have been published in the May edition of Life Science Leader magazine.

Celerion was recognized as a CRO Leader in categories including Capabilities, Compatibility, Expertise, Quality and Reliability by both big and small pharma clients.

Additionally, Individual Attribute Awards were developed in response to the intangible capabilities that were identified as critical to successful collaborations. Celerion was recognized for achievement in Data Quality, Innovative Solutions and Operational Excellence.

“It is an honor to be recognized by our clients with these awards. Celerion delivers Applied Translational Medicine to help our clients generate key data very early and enable faster go/no-go decisions. These awards reinforce our commitment to responding to our clients’ challenges in drug development,” said Susan Thornton, president and CEO.

Translating science into medicine, Celerion is a premier provider of translational clinical pharmacology sciences from their global locations including North America, Europe and Asia.

Celerion conducts first-in-human, clinical proof-of-concept and patient dose response studies, cardiovascular safety and NDA-enabling clinical pharmacology research. Celerion provides full study services including statistics, data management and biostatistics (including PK/PD analysis), and bioanalytical services.